The outcomes of transcatheter adrenal ablation in patients with primary aldosteronism: a systematic review and meta-analysis

Yang, Shunfan; Wang, Guoliang; Li, Nanfang; Zhu, Qing

doi:10.1186/s12902-023-01356-9

Table 2 Characteristics of the included studies

From: The outcomes of transcatheter adrenal ablation in patients with primary aldosteronism: a systematic review and meta-analysis

Study, Years	Country	Study type	Ablation patients	Mean age ± SD (year)	Male (%)	PA subtype	Outcome criteria	follow-up times(months)	Clinical success rate (%)	Biochemical success rate (%)
Dong 2021 [10]	China	Prospective	39	41.0 ± 9.4	29 (70.7)	bilateral	Other^a	≥ 12	0.46	NA
Hokotate 2003 [16]	Japan	Prospective	33	47.0 ± 8.0	25 (75.8)	Unilateral	Other^b	≥ 6	0.58	NA
Sun 2022 [17]	China	Prospective	52	45.0 ± 11.9	23 (44.2)	Unilateral	PASO	≥ 6	0.85	0.90
Zhang 2020 [11]	China	Prospective	36	48.4 ± 12.5	21 (58.3)	Unilateral + bilateral	PASO	≥ 6	0.61	0.44
Zhou 2022 [18]	China	Prospective	74	54.2 ± 10.9	19 (25.7)	Unilateral + bilateral	PASO	≥ 6	0.82	0.82

NA Not available
PASO: Complete clinical success is defined as normal blood pressure without the aid of antihypertensive medication. Partial clinical success is defined as the same blood pressure as before ablation with less antihypertensive medication or a reduction in blood pressure with either the same amount or less antihypertensive medication. Absent clinical success is defined as unchanged or increased blood pressure with either the same amount or an increase in antihypertensive medication. Complete biochemical success is defined as correction of hypokalaemia (if present pre-ablation) and normalisation of the aldosterone-to-renin ratio; in patients with a raised aldosterone-to-renin ratio post surgery, aldosterone secretion should be suppressed in a confirmatory Test. Partial biochemical success is defined as correction of hyqpokalaemia (if present pre-surgery) and a raised aldosterone-to-renin ratio with one or both of the following (compared with pre-surgery): decrease in baseline plasma aldosterone concentration ≥ 50%; or abnormal but improved post-surgery confirmatory test result. Absent biochemical success is defined as persistent hypokalaemia (if present pre-surgery) or persistent raised aldosterone-to-renin ratio, or both, with failure to suppress aldosterone secretion with a post-surgery confirmatory test
Other^a: Marked improvement is defined as a reduction in the home systolic or diastolic blood pressure by > 20 mmHg or > 10 mmHg, respectively, without the use of MRA, while the dosage of other antihypertensive drugs remained unchanged or reduced. Moderate improvement is defined as a reduction in home systolic or diastolic blood pressure by 10–20 mmHg or 5–10 mmHg, respectively, without the use of MRA or with its dose reduced to half, while the dosage of other antihypertensive drugs remained unchanged or reduced
Other^b: Normalization is defined as blood pressure lower than 140/90 mm Hg without the use of antihypertensive medication. Marked improvement is defined as a decrease of at least 20 mmHg in thesystolic or diastolic blood pressure either without the use of antihypertensive medication or with a decrease in antihypertensive medication dosage

Back to article page

ISSN: 1472-6823

Contact us

General enquiries: journalsubmissions@springernature.com

BMC Endocrine Disorders

Contact us